Treatment of inappropriate secretion of thyrotropin with somatostatin analog sms 201-995

Paolo Beck-Peccoz, G. Medri, G. Piscitelli, S. Mariotti, A. Bertoli, A. Barbarino, M. Rondena, E. Martino, A. Pinchera, G. Faglia

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Inappropriate thyrotropin secretion (1ST) may originate from either neoplastic disease (nIST) or non-neoplastic resistance to thyroid hormone (nnIST). An inhibitory effect of somatostatin on TSH secretion has been documented. In an attempt to elucidate the possible therapeutic effect of this peptide on nIST and nnIST, a study was conducted in 7 such patients. Sandostatin (SMS 201-995) was administered in daily doses of 100 pg for several days to 1 month. Four patients with nIST responded with a fall in circulating TSH as well as a-subunit with concomitant normalization of free thyroxine and clear symptomatic improvement. In the 3 nnIST patients this effect was considerably less apparent and a partial TSH escape was observed on long-term treatment in 2 cases. The importance of somatostatin and its analogs in the management of thyroid malignancy is stressed.

Original languageEnglish
Pages (from-to)121-123
Number of pages3
JournalHormone Research in Paediatrics
Volume29
Issue number2-3
DOIs
Publication statusPublished - 1988

Fingerprint

Thyrotropin
Somatostatin
Octreotide
Thyroid Hormone Resistance Syndrome
Therapeutic Uses
Thyroxine
Thyroid Gland
Therapeutics
Peptides
Neoplasms

Keywords

  • Hyperthyroidism
  • Inappropriate secretion of tsh
  • Pituitary resistance
  • Somatostatin
  • Somatostatin analogs
  • Thyroid hormone action
  • TSH-secreting pituitary tumors

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health

Cite this

Beck-Peccoz, P., Medri, G., Piscitelli, G., Mariotti, S., Bertoli, A., Barbarino, A., ... Faglia, G. (1988). Treatment of inappropriate secretion of thyrotropin with somatostatin analog sms 201-995. Hormone Research in Paediatrics, 29(2-3), 121-123. https://doi.org/10.1159/000180986

Treatment of inappropriate secretion of thyrotropin with somatostatin analog sms 201-995. / Beck-Peccoz, Paolo; Medri, G.; Piscitelli, G.; Mariotti, S.; Bertoli, A.; Barbarino, A.; Rondena, M.; Martino, E.; Pinchera, A.; Faglia, G.

In: Hormone Research in Paediatrics, Vol. 29, No. 2-3, 1988, p. 121-123.

Research output: Contribution to journalArticle

Beck-Peccoz, P, Medri, G, Piscitelli, G, Mariotti, S, Bertoli, A, Barbarino, A, Rondena, M, Martino, E, Pinchera, A & Faglia, G 1988, 'Treatment of inappropriate secretion of thyrotropin with somatostatin analog sms 201-995', Hormone Research in Paediatrics, vol. 29, no. 2-3, pp. 121-123. https://doi.org/10.1159/000180986
Beck-Peccoz P, Medri G, Piscitelli G, Mariotti S, Bertoli A, Barbarino A et al. Treatment of inappropriate secretion of thyrotropin with somatostatin analog sms 201-995. Hormone Research in Paediatrics. 1988;29(2-3):121-123. https://doi.org/10.1159/000180986
Beck-Peccoz, Paolo ; Medri, G. ; Piscitelli, G. ; Mariotti, S. ; Bertoli, A. ; Barbarino, A. ; Rondena, M. ; Martino, E. ; Pinchera, A. ; Faglia, G. / Treatment of inappropriate secretion of thyrotropin with somatostatin analog sms 201-995. In: Hormone Research in Paediatrics. 1988 ; Vol. 29, No. 2-3. pp. 121-123.
@article{1f28a720142148818e05d4d1011f8187,
title = "Treatment of inappropriate secretion of thyrotropin with somatostatin analog sms 201-995",
abstract = "Inappropriate thyrotropin secretion (1ST) may originate from either neoplastic disease (nIST) or non-neoplastic resistance to thyroid hormone (nnIST). An inhibitory effect of somatostatin on TSH secretion has been documented. In an attempt to elucidate the possible therapeutic effect of this peptide on nIST and nnIST, a study was conducted in 7 such patients. Sandostatin (SMS 201-995) was administered in daily doses of 100 pg for several days to 1 month. Four patients with nIST responded with a fall in circulating TSH as well as a-subunit with concomitant normalization of free thyroxine and clear symptomatic improvement. In the 3 nnIST patients this effect was considerably less apparent and a partial TSH escape was observed on long-term treatment in 2 cases. The importance of somatostatin and its analogs in the management of thyroid malignancy is stressed.",
keywords = "Hyperthyroidism, Inappropriate secretion of tsh, Pituitary resistance, Somatostatin, Somatostatin analogs, Thyroid hormone action, TSH-secreting pituitary tumors",
author = "Paolo Beck-Peccoz and G. Medri and G. Piscitelli and S. Mariotti and A. Bertoli and A. Barbarino and M. Rondena and E. Martino and A. Pinchera and G. Faglia",
year = "1988",
doi = "10.1159/000180986",
language = "English",
volume = "29",
pages = "121--123",
journal = "Hormone Research in Paediatrics",
issn = "1663-2818",
publisher = "S. Karger AG",
number = "2-3",

}

TY - JOUR

T1 - Treatment of inappropriate secretion of thyrotropin with somatostatin analog sms 201-995

AU - Beck-Peccoz, Paolo

AU - Medri, G.

AU - Piscitelli, G.

AU - Mariotti, S.

AU - Bertoli, A.

AU - Barbarino, A.

AU - Rondena, M.

AU - Martino, E.

AU - Pinchera, A.

AU - Faglia, G.

PY - 1988

Y1 - 1988

N2 - Inappropriate thyrotropin secretion (1ST) may originate from either neoplastic disease (nIST) or non-neoplastic resistance to thyroid hormone (nnIST). An inhibitory effect of somatostatin on TSH secretion has been documented. In an attempt to elucidate the possible therapeutic effect of this peptide on nIST and nnIST, a study was conducted in 7 such patients. Sandostatin (SMS 201-995) was administered in daily doses of 100 pg for several days to 1 month. Four patients with nIST responded with a fall in circulating TSH as well as a-subunit with concomitant normalization of free thyroxine and clear symptomatic improvement. In the 3 nnIST patients this effect was considerably less apparent and a partial TSH escape was observed on long-term treatment in 2 cases. The importance of somatostatin and its analogs in the management of thyroid malignancy is stressed.

AB - Inappropriate thyrotropin secretion (1ST) may originate from either neoplastic disease (nIST) or non-neoplastic resistance to thyroid hormone (nnIST). An inhibitory effect of somatostatin on TSH secretion has been documented. In an attempt to elucidate the possible therapeutic effect of this peptide on nIST and nnIST, a study was conducted in 7 such patients. Sandostatin (SMS 201-995) was administered in daily doses of 100 pg for several days to 1 month. Four patients with nIST responded with a fall in circulating TSH as well as a-subunit with concomitant normalization of free thyroxine and clear symptomatic improvement. In the 3 nnIST patients this effect was considerably less apparent and a partial TSH escape was observed on long-term treatment in 2 cases. The importance of somatostatin and its analogs in the management of thyroid malignancy is stressed.

KW - Hyperthyroidism

KW - Inappropriate secretion of tsh

KW - Pituitary resistance

KW - Somatostatin

KW - Somatostatin analogs

KW - Thyroid hormone action

KW - TSH-secreting pituitary tumors

UR - http://www.scopus.com/inward/record.url?scp=0023733938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023733938&partnerID=8YFLogxK

U2 - 10.1159/000180986

DO - 10.1159/000180986

M3 - Article

C2 - 2900192

AN - SCOPUS:0023733938

VL - 29

SP - 121

EP - 123

JO - Hormone Research in Paediatrics

JF - Hormone Research in Paediatrics

SN - 1663-2818

IS - 2-3

ER -